2018年

• January 19, 2018
  New drug approval of bile acid transporter inhibitor “GOOFICE® 5mgTablet” for chronic constipation was obtained in Japan.

2017年

• December 6, 2017
  Ulcerative Colitis Treatment“RECTABUL® 2 mg Rectal Foam 14 Doses” Launches in Japan
• November 27, 2017
  Application for Marketing and Manufacturing Approval of Chronic ConstipationTreatment AJG555 Was Filed in Japan
• October 31, 2017
  EA Pharma Signed a License Agreement with JW Pharmaceutical for Secondary Hyperparathyroidism Treatment AJT240
• September 29, 2017
  Joint Development and Marketing Agreement for Chronic Constipation Treatment AJG555 in Japan Was Signed
• September 27, 2017
  Marketing Approval for Ulcerative Colitis Treatment“RECTABUL® 2 mg Rectal Foam 14 Doses” was Obtained in Japan
• September 22, 2017
  Additional Dosage and Administration of Proton Pump Inhibitor Pariet®5 mg Tablets, 10 mg Tablets Approved in Japan forMaintenance Therapy of Proton Pump Inhibitor Resistant RefluxEsophagitis
• April 21, 2017
  EA Pharma Presents Clinical Study Data of AJG533 and Pariet®in DDW2017
• March 30, 2017
  EA Pharma Co., Ltd. Signed a Global License Agreement for Anti-MMP-9 Antibody “CALY-001” with Calypso Biotech SA
• February 1, 2017
  New Drug Application of AJG533 for chronic constipation was filed in Japan.

2016年

• October 28, 2016
  Japanese NDA for an ulcerative colitis treatment agent(Development code：AJG511) was filed.
• October 28, 2016
  Application Submitted for Proton Pump Inhibitor Pariet® in JapanSeeking Approval for Additional Dosage and Administration forMaintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis
• September 30, 2016
  EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce the results of phase 3 study of AJG533 for chronic constipation conducted in Japan
• June 20, 2016
  AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New DosingRegimen of Fully Human Anti-TNF-α Monoclonal Antibody Humira® in Patients with Crohn’s Disease
• June 13, 2016
  EISAI PRESENTS LATEST PHASE I/II DATA ON IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011　RESULTS SUGGEST SAFETY, TOLERABILITY AS WELL AS CLINICAL ACTIVITYIN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE
• June 1, 2016
  AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA® in the Field of Gastrointestinal Disease